This article was originally published in The Gray Sheet
PMA supplement covering use of TriPath's SurePath liquid-based cytology specimen collection medium for cervical cancer screening with Digene's Hybrid Capture 2 HPV DNA test would allow HPV testing directly from SurePath specimens. Formerly called CytoRich, SurePath preservation vials and density reagents were approved for use on the AutoCyte PREP system, now called PrepStain, via PMA supplement in May 2001. Digene announced the filing for the Hybrid Capture 2, currently approved as a follow-up to borderline Pap test results, April 16...
You may also be interested in...
Suspension of heartburn remedy ranitidine looming in the EU as the European Medicines Agency stands by its original decision.
Illumina announced on 21 September it will buy back Grail, which is planning to commercialize its multi-cancer early detection blood test Galleri in 2021. See what Illumina’s CEO Francis deSouza said about it here.
Yes, Gottlieb’s in there twice; things get complicated when an agency starts to lose credibility.